University of Cologne

EQS-News: Marco Santos to become CEO of GFT Technologies SE

Retrieved on: 
Wednesday, April 10, 2024
Deutsche Bank, Professional, Champaign–Urbana metropolitan area, Administration, STRABAG AG, Growth, USP, Computer science, CFO, Trust, MIT, Artificial intelligence, University of Cologne, Organic, Inc., GFT, University, Head, MBA, Bachelor, STEM, Tata Consultancy Services, STRABAG, International business, Singularity Group, Management

Stuttgart, 26 March 2024 – The Administrative Board of GFT Technologies SE today appointed Marco Santos as the new CEO of the digitalisation group.

Key Points: 
  • Stuttgart, 26 March 2024 – The Administrative Board of GFT Technologies SE today appointed Marco Santos as the new CEO of the digitalisation group.
  • In addition to his current role, Jochen Ruetz (56), CFO of GFT Technologies SE, will become Deputy CEO as of 1 January 2025.
  • Ulrich Dietz, Chairman of the Administrative Board of GFT Technologies, said: “Marco Santos is a guarantor of growth and innovation.
  • I am sure that GFT will continue to develop successfully with the new team.”
    Marco Santos has been appointed CEO of GFT.

Marco Santos to become CEO of GFT Technologies SE

Retrieved on: 
Wednesday, March 27, 2024
Networks, Data Management, Apps, Applications, Technology, Software, Deutsche Bank, Professional, Champaign–Urbana metropolitan area, STRABAG AG, Growth, USP, Computer science, CFO, Trust, MIT, Artificial intelligence, University of Cologne, Organic, Inc., GFT, University, Head, MBA, Bachelor, STEM, Tata Consultancy Services, STRABAG, International business, Singularity Group, Management

The Administrative Board of GFT Technologies SE today appointed Marco Santos as the new CEO of the digitalization group.

Key Points: 
  • The Administrative Board of GFT Technologies SE today appointed Marco Santos as the new CEO of the digitalization group.
  • In addition to his current role, Jochen Ruetz (56), CFO of GFT Technologies SE, will become Deputy CEO as of 1 January 2025.
  • Ulrich Dietz, Chairman of the Administrative Board of GFT Technologies, said: “Marco Santos is a guarantor of growth and innovation.
  • He has many years of capital market and business experience and has been CFO of GFT Technologies SE since 2003.

IBM Debuts Next-Generation Quantum Processor & IBM Quantum System Two, Extends Roadmap to Advance Era of Quantum Utility

Retrieved on: 
Monday, December 4, 2023
Quantum, Argonne National Laboratory, Basque Country (greater region), Computer, Record, NYSE, Chemistry, Organization, Physics, IBM Quantum Experience, University of California, Berkeley, Synthetic media, Collection, Electronics, Eagle, IBM, IBM Fellow, University, Algorithm, Science, Donostia International Physics Center, IBM Eagle, Software, Communication, University of Cologne, Harvard University, Architecture, Microscope, Typesetting, Television, Research, Qiskit

IBM also unveiled IBM Quantum System Two , the company's first modular quantum computer and cornerstone of IBM's quantum-centric supercomputing architecture.

Key Points: 
  • IBM also unveiled IBM Quantum System Two , the company's first modular quantum computer and cornerstone of IBM's quantum-centric supercomputing architecture.
  • The first IBM Quantum System Two, located in Yorktown Heights, New York, has begun operations with three IBM Heron processors and supporting control electronics.
  • IBM Quantum System Two is the foundation of IBM's next generation quantum computing system architecture.
  • As part of the newly expanded ten-year IBM Quantum Development Roadmap, IBM plans for this system to also house IBM's future generations of quantum processors.

IBM Debuts Next-Generation Quantum Processor & IBM Quantum System Two, Extends Roadmap to Advance Era of Quantum Utility

Retrieved on: 
Monday, December 4, 2023
Quantum, Argonne National Laboratory, Basque Country (greater region), Computer, Record, NYSE, Chemistry, Organization, Physics, IBM Quantum Experience, University of California, Berkeley, Synthetic media, Collection, Electronics, Eagle, IBM, IBM Fellow, University, Algorithm, Science, Donostia International Physics Center, IBM Eagle, Software, Communication, University of Cologne, Harvard University, Architecture, Microscope, Typesetting, Television, Research, Qiskit

IBM also unveiled IBM Quantum System Two , the company's first modular quantum computer and cornerstone of IBM's quantum-centric supercomputing architecture.

Key Points: 
  • IBM also unveiled IBM Quantum System Two , the company's first modular quantum computer and cornerstone of IBM's quantum-centric supercomputing architecture.
  • The first IBM Quantum System Two, located in Yorktown Heights, New York, has begun operations with three IBM Heron processors and supporting control electronics.
  • IBM Quantum System Two is the foundation of IBM's next generation quantum computing system architecture.
  • As part of the newly expanded ten-year IBM Quantum Development Roadmap, IBM plans for this system to also house IBM's future generations of quantum processors.

Eighteenth edition of Fujio Cup Quiz won by Kasturba Medical College, India in the NCRM NICHE 2023 international stem cell meeting.

Retrieved on: 
Wednesday, October 18, 2023
Research, Hospitals, Health Technology, Stem Cells, Biotechnology, Training, University, Health, Science, Education, Cellular senescence, Regenerative medicine, PD, Cell biology, Urethral stricture, IDC, Tissue engineering, FCQ, Sri Ramachandra Institute of Higher Education and Research, Cell, GSZ, Multimedia, Tree (graph theory), Code, Tissue, German Society for Stem Cell Research, Genome, Kasturba Medical College, Disease, Buccal, University of Cologne, Duchenne muscular dystrophy, XVIII, Radboud University Medical Center, Hospital, Chondrocyte, McEwen Centre for Regenerative Medicine, Stem cell, Multiple sclerosis, NCRM, Thai-Nichi Institute of Technology, Safety, DMD, Autism spectrum, Synthetic biology, ASD, Edogawa, MS, B cell, Pharmaceutical industry, RM

This press release features multimedia.

Key Points: 
  • This press release features multimedia.
  • Winners and finalists of Fujio Cup Quiz (FCQ), the “FCQ Elites” are qualified to nominate the candidates for the Edogawa NICHE Prize.
  • The inaugural prize in 2018 was awarded to Prof. James E. Till for discovery of stem cells, jointly with Prof. Ernest McCulloch.
  • NCRM NICHE team is progressing in research on implications of microgravity, synthetic chemical concoctions, and biological response modifiers, on cellular senescence and immune modulation to develop solutions, especially for rare diseases and unmet needs.

JenaValve Announces ALIGN-AR Pivotal Data to be Presented During the Late-Breaking Clinical Trial Sessions at TCT 2023

Retrieved on: 
Tuesday, September 19, 2023
Aortic stenosis, University, Trilogy, THV, CE marking, Booth, TCT, University of Cologne, Patient, TAVR, Aortic regurgitation, IDE, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, AR, Food, Safety, Pharmaceutical industry

The presentation will take place on Tuesday, October 24th, at 12:06 PM Pacific Time.

Key Points: 
  • The presentation will take place on Tuesday, October 24th, at 12:06 PM Pacific Time.
  • Prior to the data presentation, at 11:00 AM Pacific Time, a procedure using the CE Mark approved Trilogy THV System will be shown via broadcast from the University of Cologne.
  • Results from the study are intended to support a Premarket Approval submission to the U.S. Food and Drug Administration (FDA).
  • For additional information on the ALIGN-AR Trial or JenaValve, visit the JenaValve team at Booth #215 at TCT.

Newfound Brain Circuit Explains Why Infant Cries Prompt Milk Release

Retrieved on: 
Wednesday, September 20, 2023
Learning, Neuron, Human, Food, Princeton Neuroscience Institute, Nature, Natural science, University, Nursing, Engineering, NYU Langone Health, Mammal, NYU, New York University Grossman School of Medicine, Physiology, Brain, Doctor of Philosophy, National Institutes of Health, PIL, Bangladesh Technical Education Board, Hormone, Oxytocin, Mother, Thalamus, Protein, University of Cologne, Johns Hopkins University, Hearing, Brain cell, Hypothalamus, Lactation, Mouse, Observation, Infant, Female, Fatigue, Breast milk, Dairy, Medical imaging, Genetics

Led by researchers at NYU Grossman School of Medicine, the study explored a centuries-old observation in humans and other mammals that when a baby begins a feeding session, its cries alone can prompt its mother to release breast milk.

Key Points: 
  • Led by researchers at NYU Grossman School of Medicine, the study explored a centuries-old observation in humans and other mammals that when a baby begins a feeding session, its cries alone can prompt its mother to release breast milk.
  • This sensory hub then sends signals to oxytocin-releasing brain cells (neurons) in another region called the hypothalamus, a control center for hormone activity.
  • In addition, the mothers' brain circuitry only responded to her pups' cries and not to computer-generated tones designed to mimic natural wails.
  • Then, in a form of "reverse engineering," they traced how sound information travels through different areas of the brain to trigger milk flow.

Sentynl Therapeutics Announces Presentation of Study Evaluating the Efficacy and Safety of NULIBRY® (fosdenopterin) for the Treatment of MoCD Type A at 2023 SSIEM Annual Symposium

Retrieved on: 
Thursday, September 7, 2023
Seizure, Consultant, Infection, European Medicines Agency, Encephalopathy, Survival, Necrotizing enterocolitis, Genetic distance, Cox, Whole genome sequencing, Biochemistry, Molecular medicine, Ministry, Fosdenopterin, RSV, Patient, University of Cologne, Risk, Chemistry, Growth, Mortality, Saint Mary's Hospital, Hospital, Rare, Caregiver, Therapy, Death, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Molybdenum cofactor deficiency, Pneumonia, Food, Safety, Pharmaceutical industry, Metabolism, Health

SOLANA BEACH, Calif., Sept. 7, 2023 /PRNewswire/ -- Sentynl Therapeutics, Inc. (Sentynl), a U.S.-based biopharmaceutical company focused on bringing innovative therapies to patients living with rare diseases, announced that data evaluating NULIBRY® (fosdenopterin) for the treatment of patients with molybdenum cofactor deficiency (MoCD) Type A were presented at the 2023 Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Meeting on Aug. 30 in Jerusalem. NULIBRY is indicated to reduce the risk of mortality in patients with MoCD Type A, an ultra-rare, autosomal recessive, inborn error of metabolism causing sulfite-induced neurodegeneration and early death.

Key Points: 
  • NULIBRY is indicated to reduce the risk of mortality in patients with MoCD Type A, an ultra-rare, autosomal recessive, inborn error of metabolism causing sulfite-induced neurodegeneration and early death.
  • "Early treatment with fosdenopterin (NULIBRY) improves survival and neurodevelopmental outcomes, reducing burden on patients and caregivers."
  • Treatment with rcPMP/NULIBRY led to a normalization of MoCD Type A-associated urinary biomarker levels.
  • To further evaluate the safety and efficacy of NULIBRY, a post-approval non-interventional study is being initiated in Europe.

AmerisourceBergen Elects Werner Baumann and Lauren Tyler to Its Board of Directors

Retrieved on: 
Tuesday, August 15, 2023
Veterinary, Pharmaceutical, Finance, General Health, Health, Banking, Professional Services, Health Insurance, Berkshire Hathaway, Yale University, Human resources, University, AmerisourceBergen, JPMorgan Chase, Bayer, Economics, RWTH Aachen University, University of Cologne, Retirement, Acquisition, Alleghany Corporation, ABC, Harvard Business School, Development, NYSE, Management

AmerisourceBergen Corporation (NYSE: ABC) today announced that its Board of Directors has elected Werner Baumann and Lauren M. Tyler as new independent directors, effective October 1, 2023.

Key Points: 
  • AmerisourceBergen Corporation (NYSE: ABC) today announced that its Board of Directors has elected Werner Baumann and Lauren M. Tyler as new independent directors, effective October 1, 2023.
  • With the election of Mr. Baumann and Ms. Tyler, the Board of Directors will increase from ten to twelve members, ten of whom are independent.
  • “We look forward to welcoming Mr. Baumann and Ms. Tyler to AmerisourceBergen’s Board of Directors.
  • Ms. Tyler was a director at Alleghany Corporation from January 2019 until its acquisition by Berkshire Hathaway in October 2022.

Akamis Bio Strengthens Leadership Team with Key Executive Appointments

Retrieved on: 
Thursday, July 6, 2023
Biotechnology, Health, Genetics, Pharmaceutical, Oncology, Yale University, Mace Head Atmospheric Research Station, MIT Sloan School of Management, Business development, Novartis Institute for Tropical Diseases, Research strategies of election campaign communication research, Bluebird bio, Therapy, Biochemistry, Senior, University, Doctor of Philosophy, Bio, Feinberg School of Medicine, University of Hamburg, Business, Bayer, DRS, MBA, Biomedical Research, CMO, Genentech, MIT, Associate, Teaching hospital, PBMC, Harvard Medical School, Research and development, Multiple Myeloma Research Foundation, Takeda Oncology, University of Cologne, Patient, CBO, CD40, Hematology, Swarthmore College, Northwestern University, SQZ, Multiple myeloma, Pharmaceutical industry, Management, Research

as Chief Medical Officer (CMO), Peter Kosa, Ph.D. as Chief Business Officer (CBO), and Samantha Bailey-Bucktrout, Ph.D. as Senior Vice President, Head of Research.

Key Points: 
  • as Chief Medical Officer (CMO), Peter Kosa, Ph.D. as Chief Business Officer (CBO), and Samantha Bailey-Bucktrout, Ph.D. as Senior Vice President, Head of Research.
  • “As CMO, Oliver’s decades of experience in oncology drug development will be critical as we advance our lead program, NG-350A, toward clinical proof-of-concept studies.
  • Dr. Kosa has also held leadership positions at XOMA, Bayer Healthcare, and Connecticut Innovations.
  • She joined Akamis Bio from the Parker Institute for Cancer Immunotherapy in San Francisco where she was Senior Director of Research and Development.